

7. Literatur

1. Andersen JR, Steven K. Implantation metastasis after laparoscopic biopsy of bladder cancer. *J.Urol.* 1995;153(3 Pt 2):1047-8.
2. Anderson LM, Souliotis VL, Chhabra SK, Moskal TJ, Harbaugh SD, Kyrtopoulos SA. N-nitrosodimethylamine-derived O(6)-methylguanine in DNA of monkey gastrointestinal and urogenital organs and enhancement by ethanol. *Int.J.Cancer* 1996;66(1):130-4.
3. Andrew AS, Schned AR, Heaney JA, Karagas MR. Bladder cancer risk and personal hair dye use. *Int.J.Cancer* 2004;109(4):581-6.
4. Bachor R, Flotte TJ, Scholz M, Dretler S, Hasan T. Comparison of intravenous and intravesical administration of chloro-aluminum sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model. *J.Urol.* 1992;147(5):1404-10.
5. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. *Cytokine* 1991;3(6):568-75.
6. Bellmunt J, Albiol S. Chemotherapy for metastatic or unresectable bladder cancer. *Semin.Oncol.* 2007;34(2):135-44.
7. Bisson JF, Parache RM, Droulle P, Notter D, Vigneron C, Guillemin F. A new method of implanting orthotopic rat bladder tumor for experimental therapies. *Int.J.Cancer* 2002;102(3):280-5.
8. Bonney WW, Henstorf JE, Emaus SP, Lubaroff DM, Feldbush TL. Immunostimulation by cryosurgery: an orthotopic model of prostate and bladder cancer in the rat. *Natl.Cancer Inst.Monogr* 1978(49):375-81.
9. Braumann C, Henke W, Jacobi CA, Dubiel W. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. *Int.J.Cancer* 2004;112(2):225-30.
10. Braumann C, Ordemann J, Kilian M, Wenger FA, Jacobi CA. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. *Clin.Exp.Metastasis* 2003;20(5):387-94.
11. Braumann C, Schoenbeck M, Menenakos C, Kilian M, Jacobi CA. Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. *Clin.Exp.Metastasis* 2005;22(1):77-83.

12. Bretz, M. Taurin, Chemie, Biochemie, Anwendung; Seminararbeit von Michael Bretz. Bayerische Julius Maximilians Universität Würzburg, Institut für Pharmazie und Lebensmittelchemie, Lehrstuhl für Lebensmittelchemie, Prof.Dr.P.Schreiner , 1-40. 2002.
13. Brod JL, Kuhn R, Schafhauser W, Schrott KM. Radiochemotherapy in locally invasive non-metastatic carcinoma of the bladder. *Adv.Exp.Med.Biol.* 2003;539(Pt A):143-53.
14. Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. *Cancer Res.* 2001;61(18):6816-21.
15. Carter JJ, Whelan RL. The immunologic consequences of laparoscopy in oncology. *Surg Oncol.Clin.N.Am.* 2001;10(3):655-77.
16. Castronovo V, Taraboletti G, Sobel ME. Laminin receptor complementary DNA-deduced synthetic peptide inhibits cancer cell attachment to endothelium. *Cancer Res.* 1991;51(20):5672-8.
17. Cava A, Roman J, Gonzalez QA, Martin F, Aramburo P. Subcutaneous metastasis following laparoscopy in gastric adenocarcinoma. *Eur.J.Surg Oncol.* 1990;16(1):63-7.
18. Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY et al. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach. *Jpn.J.Clin.Oncol.* 2004;34(4):202-5.
19. Cohen SM, Shirai T, Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. *Scand.J.Urol.Nephrol.Suppl* 2000(205):105-15.
20. Da Costa ML, Redmond HP, Bouchier-Hayes DJ. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. *J.Surg.Res.* 2001;101(2):111-9.
21. Djousse L, Gaziano JM. Alcohol consumption and risk of heart failure in the Physicians' Health Study I. *Circulation* 2007;115(1):34-9.
22. Gago-Dominguez M, Bell DA, Watson MA, Yuan JM, Castelao JE, Hein DW et al. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. *Carcinogenesis* 2003;24(3):483-9.
23. Gambacorti-Passerini C, Barni R, Le Coutre P, Zucchetti M, Cabrita G, Cleris L et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. *J.Natl.Cancer Inst.* 2000;92(20):1641-50.
24. Gibas Z, Gibas L. Cytogenetics of bladder cancer. *Cancer Genet.Cytogenet.* 1997;95(1):108-15.

25. Goldstein DS, Lu ML, Hattori T, Ratliff TL, Loughlin KR, Kavoussi LR. Inhibition of peritoneal tumor-cell implantation: model for laparoscopic cancer surgery. *J.Endourol.* 1993;7(3):237-41.
26. Gorman SP, McCafferty DF, Woolfson AD, Jones DS. A comparative study of the microbial antiadherence capacities of three antimicrobial agents. *J.Clin.Pharm.Ther.* 1987;12(6):393-9.
27. Gronlund-Pakkanen S, Wahlfors J, Talja M, Kosma VM, Pakkanen TM, Ala-Opas M et al. The effect of photodynamic therapy on rat urinary bladder with orthotopic urothelial carcinoma. *BJU.Int.* 2003;92(1):125-30.
28. Hamdy FC, Basler JW, Neal DE, Catalona WJ. Management of Urologic Malignancies, Churchill Livingstone, London, Edinburgh, New-York, Philadelphia, St. Louis, Tokyo, Sydney, Toronto. 11-55. 2002.
29. Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. *Anticancer Res.* 2002;22(4):1959-64.
30. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. *Mutat.Res.* 2002;506-507:65-77.
31. Herr HW, Jakse G, Sheinfeld J. The T1 bladder tumor. *Semin.Urol.* 1990;8(4):254-61.
32. Highley MS, Van Oosterom AT, Maes RA, De Bruijn EA. Intravesical drug delivery. Pharmacokinetic and clinical considerations. *Clin.Pharmacokinet.* 1999;37(1):59-73.
33. Hudson MA. When intravesical measures fail. Indications for cystectomy in superficial disease. *Urol.Clin.North Am.* 1992;19(3):601-9.
34. Hyacinthe LM, Jarrett TW, Gordon CS, Vaughan ED, Jr., Whalen GF. Inhibition of bladder tumor cell implantation in cauterized urothelium, without inhibition of healing, by a fibronectin-related peptide (GRGDS). *Ann Surg Oncol.* 1995;2(5):450-6.
35. Jacobi CA, Bouchier-Hayes DJ, Braumann C, Brock M, Pfirrmann RW, Redmond HP et al. Taurolidin in der Tumorthherapie-Vorstellung eines neuen Therapiekonzeptes. Uni-Med Verlag, Bremen, London, München. 18-79. 1ed. 2003.
36. Jacobi CA, Menenakos C, Braumann C. Taurolidine--a new drug with anti-tumor and anti-angiogenic effects. *Anticancer Drugs* 2005;16(9):917-21.
37. Jacobi CA, Ordemann J, Bohm B, Zieren HU, Sabat R, Muller JM. Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. *Am.J.Surg.* 1997;174(3):359-63.

38. Kaidi AA, Nazzal M, Gurchumelidze T, Ali MA, Dawe EJ, Silva YJ. Preoperative administration of antibodies against tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and their impact on peritoneal adhesion formation. *Am.Surg.* 1995;61(7):569-72.
39. Kalble T. [Etiopathology, risk factors, environmental influences and epidemiology of bladder cancer]. *Urologe A* 2001;40(6):447-50.
40. Kamuhabwa AA, Roskams T, D'Hallewin MA, Baert L, van Poppel H, de Witte PA. Whole bladder wall photodynamic therapy of transitional cell carcinoma rat bladder tumors using intravesically administered hypericin. *Int.J.Cancer* 2003;107(3):460-7.
41. Kasachenko VM, Briskin BS, Evstifeeva OV, Savchenko ZI. [The impact of the type of anesthesia on stress-realizing and stress-limiting mechanisms of the immune system in gerontological patients at abdominal surgeries]. *Eksp.Klin.Gastroenterol.* 2004(3):58-61, 105.
42. Kemberling JK, Hampton JA, Keck RW, Gomez MA, Selman SH. Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. *J.Urol.* 2003;170(3):773-6.
43. Knight A, Askling J, Granath F, Sparen P, Ekbohm A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. *Ann Rheum.Dis.* 2004;63(10):1307-11.
44. Knight BI, Skellern GG, Browne MK, Pfirrmann RW. Peritoneal absorption of the antibacterial and antiendotoxin taurolin in peritonitis. *Br.J.Clin.Pharmacol.* 1981;12(5):695-9.
45. Knowles MA. Identification of novel bladder tumour suppressor genes. *Electrophoresis* 1999;20(2):269-79.
46. Lamm SH, Engel A, Kruse MB, Feinleib M, Byrd DM, Lai S et al. Arsenic in drinking water and bladder cancer mortality in the United States: an analysis based on 133 U.S. counties and 30 years of observation. *J.Occup.Environ.Med.* 2004;46(3):298-306.
47. Lardner A. The effects of extracellular pH on immune function. *J.Leukoc.Biol.* 2001;69(4):522-30.
48. Leebeek FW, Ouwendijk RJ, Kolk AH, Dees A, Meek JC, Nienhuis JE et al. Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation. *Gut* 1996;38(4):616-8.
49. Liedl, B., Zaak, D., Schwaibold, H., Zimmermann, F., Treiber, U., Weiss, M., *Manual Urogenitale Tumoren, Harnblasenkarzinom.* Tumorzentrum München und W.Zuckerschwerdt Verlag München. 43-77. 2003.

50. Lin J, Spitz MR, Wang Y, Schabath MB, Gorlov IP, Hernandez LM et al. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. *Carcinogenesis* 2004;25(9):1639-47.
51. Markovic SN, Murasko DM. Anesthesia inhibits interferon-induced natural killer cell cytotoxicity via induction of CD8+ suppressor cells. *Cell Immunol.* 1993;151(2):474-80.
52. McCourt M, Wang JH, Sookhai S, Redmond HP. Taurolidine inhibits tumor cell growth in vitro and in vivo. *Ann.Surg.Oncol.* 2000;7(9):685-91.
53. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. *Anesth.Analg.* 2003;97(5):1331-9.
54. Meyer JP, Persad R, Gillatt DA. Use of bacille Calmette-Guerin in superficial bladder cancer. *Postgrad.Med.J.* 2002;78(922):449-54.
55. Nici L, Monfils B, Calabresi P. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. *Clin.Cancer Res.* 2004;10(22):7655-61.
56. O'Grady SM, Lee SY. Molecular diversity and function of voltage-gated (Kv) potassium channels in epithelial cells. *Int.J.Biochem.Cell Biol.* 2005;37(8):1578-94.
57. Omer B, Ozbek U, Akkose A, Kilic G. Genetic polymorphism of cytochrome P450 2E1 in the Turkish population. *Cell Biochem.Funct.* 2001;19(4):273-5.
58. Oyasu R. Epithelial tumours of the lower urinary tract in humans and rodents. *Food Chem.Toxicol.* 1995;33(9):747-55.
59. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. *Br.J.Cancer* 1999;81(8):1311-7.
60. Pollmann C, Huang X, Mall J, Bech-Otschir D, Naumann M, Dubiel W. The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells. *Cancer Res.* 2001;61(23):8416-21.
61. Qizilbash AH. Radiation-induced carcinoma of the rectum. A late complication of pelvic irradiation. *Arch.Pathol.* 1974;98(2):118-21.
62. Riede UN, Schaefer HE. *Allgemeine und spezielle Pathologie.* Georg Thieme Verlag; Stuttgart, New-York.; 1999.
63. Rubin H. Magnesium: The missing element in molecular views of cell proliferation control. *Bioessays* 2005;27(3):311-20.
64. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. *Science* 1987;238(4826):491-7.

65. Salagovic J, Kalina I, Habalova V, Hrivnak M, Valansky L, Biroš E. The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. *Physiol Res.* 1999;48(6):465-71.
66. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. *FEMS Microbiol.Lett.* 2003;226(2):195-202.
67. Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. *J.Pathol.* 1998;185(4):345-51.
68. Spruck CH, III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC et al. Two molecular pathways to transitional cell carcinoma of the bladder. *Cancer Res.* 1994;54(3):784-8.
69. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W et al. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. *Anticancer Res.* 2004;24(2C):1143-7.
70. Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Mohler H. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. *Anticancer Res.* 2003;23(3B):2309-14.
71. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. *Cancer Epidemiol.Biomarkers Prev.* 2002;11(9):939-43.
72. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. *J.Biol.Chem.* 2004;279(10):8567-76.
73. Tsukada K, Katoh H, Shiojima M, Suzuki T, Takenoshita S, Nagamachi Y. Concentrations of cytokines in peritoneal fluid after abdominal surgery. *Eur.J.Surg* 1993;159(9):475-9.
74. Vogelstein B, Kinzler KW. The multistep nature of cancer. *Trends Genet.* 1993;9(4):138-41.
75. Wexner SD, Cohen SM. Port site metastases after laparoscopic colorectal surgery for cure of malignancy. *Br.J.Surg* 1995;82(3):295-8.
76. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. *Br.J.Cancer* 1999;81(4):638-46.
77. Yano S, Nokihara H, Yamamoto A, Goto H, Ogawa H, Kanematsu T et al. Multifunctional interleukin-1beta promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules. *Cancer Sci.* 2003;94(3):244-52.